Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia

The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clini...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2018-11, Vol.2 (22), p.3155-3162
Hauptverfasser: Pishko, Allyson M., Fardin, Sara, Lefler, Daniel S., Paydary, Koosha, Vega, Rolando, Arepally, Gowthami M., Crowther, Mark, Rice, Lawrence, Cines, Douglas B., Cuker, Adam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3162
container_issue 22
container_start_page 3155
container_title Blood advances
container_volume 2
creator Pishko, Allyson M.
Fardin, Sara
Lefler, Daniel S.
Paydary, Koosha
Vega, Rolando
Arepally, Gowthami M.
Crowther, Mark
Rice, Lawrence
Cines, Douglas B.
Cuker, Adam
description The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clinical team calculated the HEP score and 4Ts score. An independent panel adjudicated HIT status based on a clinical summary as well as the results of HIT laboratory testing. The prevalence of HIT in the study population was 14.7%. At a cutoff of ≥3, the HEP score was 95.3% sensitive (95% confidence interval [CI], 84.2-99.4) and 35.7% specific (95% CI, 29.8-42.0) for HIT. A 4Ts score of ≥4 had a sensitivity of 97.7% (95% CI, 86.2-99.8) and specificity of 32.9% (95% CI, 27.2-39.1). The areas under the receiver operating characteristic (ROC) curves (AUCs) for the HEP score and 4Ts score were similar (0.81 [95% CI, 0.74-0.87] vs 0.76 [95% CI, 0.69-0.83]; P = .12). The HEP score exhibited a significantly higher AUC than the 4Ts score in patients in the intensive care unit (ICU) (0.86 vs 0.79; P = .03). Among trainee scorers, the HEP score performed significantly better than the 4Ts score (AUC, 0.80 vs 0.73; P = .03). Our data suggest that either the 4Ts score or the HEP score may be used in clinical practice. The HEP score may be preferable in ICU patients and among less experienced clinicians. [Display omitted]
doi_str_mv 10.1182/bloodadvances.2018023077
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6258908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920306042</els_id><sourcerecordid>2139568012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-9b9492204c45df96c8edcdbf70c20254bc082aa6125f3bf325ef82ad6491c7b53</originalsourceid><addsrcrecordid>eNqFkU9P3DAQxS1UBAj4ClWOXAL-m8QXJIpoQUIqB3q2HHvMuk3sYGdX4tvjZZcFTj3Znvm9N9Y8hCqCzwnp6EU_xGi1XelgIJ9TTDpMGW7bPXREectqKVj7bXen8hCd5vwXY0zahglJD9Ahw7xhkogj9O8hxTyBmf0KKhPHSSefY6iiq-YFVLc3D1U2MUGlg634Y96-XExvfev1U4jZ57VgAWt1qH2wSwO2ACmOfTQvc5wgeH2C9p0eMpxuz2P05-fN4_Vtff_719311X1teCvnWvaSS0oxN1xYJxvTgTW2dy02FFPBe4M7qnVDqHCsd4wKcKVgGy6JaXvBjtHlxnda9mPRQpiTHtSU_KjTi4raq6-d4BfqKa5UQ0UncVcMzrYGKT4vIc9q9NnAMOgAcZkVJUyKpsOEFrTboKbsMSdwuzEEq3Vc6ktc6iOuIv3--Zs74Xs4BfixAaAsa-UhqWw8FBvrU0lM2ej_P-UV3kyuiw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2139568012</pqid></control><display><type>article</type><title>Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Pishko, Allyson M. ; Fardin, Sara ; Lefler, Daniel S. ; Paydary, Koosha ; Vega, Rolando ; Arepally, Gowthami M. ; Crowther, Mark ; Rice, Lawrence ; Cines, Douglas B. ; Cuker, Adam</creator><creatorcontrib>Pishko, Allyson M. ; Fardin, Sara ; Lefler, Daniel S. ; Paydary, Koosha ; Vega, Rolando ; Arepally, Gowthami M. ; Crowther, Mark ; Rice, Lawrence ; Cines, Douglas B. ; Cuker, Adam</creatorcontrib><description>The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clinical team calculated the HEP score and 4Ts score. An independent panel adjudicated HIT status based on a clinical summary as well as the results of HIT laboratory testing. The prevalence of HIT in the study population was 14.7%. At a cutoff of ≥3, the HEP score was 95.3% sensitive (95% confidence interval [CI], 84.2-99.4) and 35.7% specific (95% CI, 29.8-42.0) for HIT. A 4Ts score of ≥4 had a sensitivity of 97.7% (95% CI, 86.2-99.8) and specificity of 32.9% (95% CI, 27.2-39.1). The areas under the receiver operating characteristic (ROC) curves (AUCs) for the HEP score and 4Ts score were similar (0.81 [95% CI, 0.74-0.87] vs 0.76 [95% CI, 0.69-0.83]; P = .12). The HEP score exhibited a significantly higher AUC than the 4Ts score in patients in the intensive care unit (ICU) (0.86 vs 0.79; P = .03). Among trainee scorers, the HEP score performed significantly better than the 4Ts score (AUC, 0.80 vs 0.73; P = .03). Our data suggest that either the 4Ts score or the HEP score may be used in clinical practice. The HEP score may be preferable in ICU patients and among less experienced clinicians. [Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2018023077</identifier><identifier>PMID: 30463915</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antibodies - analysis ; Anticoagulants - adverse effects ; Area Under Curve ; Clinical Trials and Observations ; Decision Support Techniques ; Female ; Heparin - adverse effects ; Humans ; Male ; Middle Aged ; Prospective Studies ; ROC Curve ; Serotonin - analysis ; Thrombocytopenia - chemically induced ; Thrombocytopenia - diagnosis</subject><ispartof>Blood advances, 2018-11, Vol.2 (22), p.3155-3162</ispartof><rights>2018 American Society of Hematology</rights><rights>2018 by The American Society of Hematology.</rights><rights>2018 by The American Society of Hematology 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-9b9492204c45df96c8edcdbf70c20254bc082aa6125f3bf325ef82ad6491c7b53</citedby><cites>FETCH-LOGICAL-c479t-9b9492204c45df96c8edcdbf70c20254bc082aa6125f3bf325ef82ad6491c7b53</cites><orcidid>0000-0002-3595-5697 ; 0000-0003-0496-5064 ; 0000-0003-4986-4873 ; 0000-0001-9997-454X ; 0000-0001-5986-504X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258908/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258908/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30463915$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pishko, Allyson M.</creatorcontrib><creatorcontrib>Fardin, Sara</creatorcontrib><creatorcontrib>Lefler, Daniel S.</creatorcontrib><creatorcontrib>Paydary, Koosha</creatorcontrib><creatorcontrib>Vega, Rolando</creatorcontrib><creatorcontrib>Arepally, Gowthami M.</creatorcontrib><creatorcontrib>Crowther, Mark</creatorcontrib><creatorcontrib>Rice, Lawrence</creatorcontrib><creatorcontrib>Cines, Douglas B.</creatorcontrib><creatorcontrib>Cuker, Adam</creatorcontrib><title>Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clinical team calculated the HEP score and 4Ts score. An independent panel adjudicated HIT status based on a clinical summary as well as the results of HIT laboratory testing. The prevalence of HIT in the study population was 14.7%. At a cutoff of ≥3, the HEP score was 95.3% sensitive (95% confidence interval [CI], 84.2-99.4) and 35.7% specific (95% CI, 29.8-42.0) for HIT. A 4Ts score of ≥4 had a sensitivity of 97.7% (95% CI, 86.2-99.8) and specificity of 32.9% (95% CI, 27.2-39.1). The areas under the receiver operating characteristic (ROC) curves (AUCs) for the HEP score and 4Ts score were similar (0.81 [95% CI, 0.74-0.87] vs 0.76 [95% CI, 0.69-0.83]; P = .12). The HEP score exhibited a significantly higher AUC than the 4Ts score in patients in the intensive care unit (ICU) (0.86 vs 0.79; P = .03). Among trainee scorers, the HEP score performed significantly better than the 4Ts score (AUC, 0.80 vs 0.73; P = .03). Our data suggest that either the 4Ts score or the HEP score may be used in clinical practice. The HEP score may be preferable in ICU patients and among less experienced clinicians. [Display omitted]</description><subject>Aged</subject><subject>Antibodies - analysis</subject><subject>Anticoagulants - adverse effects</subject><subject>Area Under Curve</subject><subject>Clinical Trials and Observations</subject><subject>Decision Support Techniques</subject><subject>Female</subject><subject>Heparin - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>ROC Curve</subject><subject>Serotonin - analysis</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Thrombocytopenia - diagnosis</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9P3DAQxS1UBAj4ClWOXAL-m8QXJIpoQUIqB3q2HHvMuk3sYGdX4tvjZZcFTj3Znvm9N9Y8hCqCzwnp6EU_xGi1XelgIJ9TTDpMGW7bPXREectqKVj7bXen8hCd5vwXY0zahglJD9Ahw7xhkogj9O8hxTyBmf0KKhPHSSefY6iiq-YFVLc3D1U2MUGlg634Y96-XExvfev1U4jZ57VgAWt1qH2wSwO2ACmOfTQvc5wgeH2C9p0eMpxuz2P05-fN4_Vtff_719311X1teCvnWvaSS0oxN1xYJxvTgTW2dy02FFPBe4M7qnVDqHCsd4wKcKVgGy6JaXvBjtHlxnda9mPRQpiTHtSU_KjTi4raq6-d4BfqKa5UQ0UncVcMzrYGKT4vIc9q9NnAMOgAcZkVJUyKpsOEFrTboKbsMSdwuzEEq3Vc6ktc6iOuIv3--Zs74Xs4BfixAaAsa-UhqWw8FBvrU0lM2ej_P-UV3kyuiw</recordid><startdate>20181127</startdate><enddate>20181127</enddate><creator>Pishko, Allyson M.</creator><creator>Fardin, Sara</creator><creator>Lefler, Daniel S.</creator><creator>Paydary, Koosha</creator><creator>Vega, Rolando</creator><creator>Arepally, Gowthami M.</creator><creator>Crowther, Mark</creator><creator>Rice, Lawrence</creator><creator>Cines, Douglas B.</creator><creator>Cuker, Adam</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3595-5697</orcidid><orcidid>https://orcid.org/0000-0003-0496-5064</orcidid><orcidid>https://orcid.org/0000-0003-4986-4873</orcidid><orcidid>https://orcid.org/0000-0001-9997-454X</orcidid><orcidid>https://orcid.org/0000-0001-5986-504X</orcidid></search><sort><creationdate>20181127</creationdate><title>Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia</title><author>Pishko, Allyson M. ; Fardin, Sara ; Lefler, Daniel S. ; Paydary, Koosha ; Vega, Rolando ; Arepally, Gowthami M. ; Crowther, Mark ; Rice, Lawrence ; Cines, Douglas B. ; Cuker, Adam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-9b9492204c45df96c8edcdbf70c20254bc082aa6125f3bf325ef82ad6491c7b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Antibodies - analysis</topic><topic>Anticoagulants - adverse effects</topic><topic>Area Under Curve</topic><topic>Clinical Trials and Observations</topic><topic>Decision Support Techniques</topic><topic>Female</topic><topic>Heparin - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>ROC Curve</topic><topic>Serotonin - analysis</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Thrombocytopenia - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pishko, Allyson M.</creatorcontrib><creatorcontrib>Fardin, Sara</creatorcontrib><creatorcontrib>Lefler, Daniel S.</creatorcontrib><creatorcontrib>Paydary, Koosha</creatorcontrib><creatorcontrib>Vega, Rolando</creatorcontrib><creatorcontrib>Arepally, Gowthami M.</creatorcontrib><creatorcontrib>Crowther, Mark</creatorcontrib><creatorcontrib>Rice, Lawrence</creatorcontrib><creatorcontrib>Cines, Douglas B.</creatorcontrib><creatorcontrib>Cuker, Adam</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pishko, Allyson M.</au><au>Fardin, Sara</au><au>Lefler, Daniel S.</au><au>Paydary, Koosha</au><au>Vega, Rolando</au><au>Arepally, Gowthami M.</au><au>Crowther, Mark</au><au>Rice, Lawrence</au><au>Cines, Douglas B.</au><au>Cuker, Adam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2018-11-27</date><risdate>2018</risdate><volume>2</volume><issue>22</issue><spage>3155</spage><epage>3162</epage><pages>3155-3162</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>The HIT Expert Probability (HEP) score compared favorably with the 4Ts score in a retrospective study. We assessed the diagnostic accuracy of the HEP score compared with the 4Ts score in a prospective cohort of 310 patients with suspected heparin-induced thrombocytopenia (HIT). A member of the clinical team calculated the HEP score and 4Ts score. An independent panel adjudicated HIT status based on a clinical summary as well as the results of HIT laboratory testing. The prevalence of HIT in the study population was 14.7%. At a cutoff of ≥3, the HEP score was 95.3% sensitive (95% confidence interval [CI], 84.2-99.4) and 35.7% specific (95% CI, 29.8-42.0) for HIT. A 4Ts score of ≥4 had a sensitivity of 97.7% (95% CI, 86.2-99.8) and specificity of 32.9% (95% CI, 27.2-39.1). The areas under the receiver operating characteristic (ROC) curves (AUCs) for the HEP score and 4Ts score were similar (0.81 [95% CI, 0.74-0.87] vs 0.76 [95% CI, 0.69-0.83]; P = .12). The HEP score exhibited a significantly higher AUC than the 4Ts score in patients in the intensive care unit (ICU) (0.86 vs 0.79; P = .03). Among trainee scorers, the HEP score performed significantly better than the 4Ts score (AUC, 0.80 vs 0.73; P = .03). Our data suggest that either the 4Ts score or the HEP score may be used in clinical practice. The HEP score may be preferable in ICU patients and among less experienced clinicians. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30463915</pmid><doi>10.1182/bloodadvances.2018023077</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3595-5697</orcidid><orcidid>https://orcid.org/0000-0003-0496-5064</orcidid><orcidid>https://orcid.org/0000-0003-4986-4873</orcidid><orcidid>https://orcid.org/0000-0001-9997-454X</orcidid><orcidid>https://orcid.org/0000-0001-5986-504X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2473-9529
ispartof Blood advances, 2018-11, Vol.2 (22), p.3155-3162
issn 2473-9529
2473-9537
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6258908
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Aged
Antibodies - analysis
Anticoagulants - adverse effects
Area Under Curve
Clinical Trials and Observations
Decision Support Techniques
Female
Heparin - adverse effects
Humans
Male
Middle Aged
Prospective Studies
ROC Curve
Serotonin - analysis
Thrombocytopenia - chemically induced
Thrombocytopenia - diagnosis
title Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A48%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20comparison%20of%20the%20HEP%20score%20and%204Ts%20score%20for%20the%20diagnosis%20of%20heparin-induced%20thrombocytopenia&rft.jtitle=Blood%20advances&rft.au=Pishko,%20Allyson%20M.&rft.date=2018-11-27&rft.volume=2&rft.issue=22&rft.spage=3155&rft.epage=3162&rft.pages=3155-3162&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2018023077&rft_dat=%3Cproquest_pubme%3E2139568012%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2139568012&rft_id=info:pmid/30463915&rft_els_id=S2473952920306042&rfr_iscdi=true